The short version
- The 40 Hz idea began in MIT mouse experiments in 2016, and the longest human follow-up published so far has 5 participants.
- Cognito’s headline figures, a 77% reduction in functional decline and 76% in cognitive decline, come from a 76-person feasibility study reported by the company, not a pivotal trial.
- The 670-patient, sham-controlled HOPE trial is fully enrolled, and its topline result, now promised before the end of 2026, is the first real test.
For about an hour a day, in living rooms across 70 US trial sites, people with early Alzheimer’s disease have been sitting with a pair of glasses that flicker and a headset that pulses, both locked to the same rhythm: 40 times a second. The device is called Spectris. The company behind it, Cognito Therapeutics, has raised $105 million this year on the hope that this rhythm slows the disease.
Before the end of 2026, we find out whether it does.
Where the rhythm came from
The brain has a native hum in the 30 to 80 Hz range that neuroscientists call gamma. In Alzheimer’s disease, the brain’s electrical activity as recorded on EEG tends to slow.
Starting in 2016, Li-Huei Tsai’s lab at MIT published mouse experiments in which driving the brain at 40 Hz with light and sound appeared to change the course of the disease in the animals. That work created a field: “gamma stimulation,” “gamma entrainment,” and, in the wellness market, “gamma frequencies” for focus.
The leap from mouse to human has been slow and small. MIT’s own long-term human follow-up, published as a 30-month report in a December 2025 supplement of Alzheimer’s & Dementia (Chan et al.), covers 5 people. Five is enough to show that people will wear the device. It is not enough to show anything else.
What Cognito has actually shown
Cognito’s evidence comes from a feasibility study called OVERTURE, with 76 patients, presented most recently at the AD/PD 2026 conference in March.
The company’s account goes like this. Over 24 weeks, treated patients showed less slowing on EEG, the scalp recording of brain electrical activity, than controls. That EEG difference correlated with less decline on a daily-living scale (ADCS-ADL) and less loss of brain volume on MRI.
The headline percentages, repeated in nearly every press mention of the company, are a 77% reduction in functional decline, a 76% reduction in cognitive decline measured by the MMSE, a 69% reduction in brain-volume loss, and 85% adherence to the daily hour.
Those are striking numbers. Here is why they are not proof.
Relative percentages hide small absolutes. A “77% reduction in decline” is a comparison of two slopes in a 76-person study over 24 weeks. We have not seen the raw point changes behind it, and on a scale like the MMSE a few points in a small group can produce a large-looking percentage. The source for every figure is the company’s own press material.
Feasibility studies are designed to answer “can we run this trial?” rather than “does this work?” They are small, their endpoints are often chosen after the fact, and favorable results in them routinely vanish in larger trials. That is not a knock on Cognito; it is the base rate across Alzheimer’s drug and device development.
The FDA has granted Spectris Breakthrough Device status, which speeds review. It is not a judgment on efficacy.
The real test
HOPE is the pivotal trial. The published descriptions put enrollment at 670 to 673 patients across 70 US sites, randomized against a sham device, with a 12-month open-label extension afterward. It is fully enrolled.
The sham arm is the part that matters. Anyone wearing flickering glasses for an hour a day expects something to happen, and expectation moves self-reported and caregiver-reported scales. Only a sham comparison can separate the 40 Hz rhythm from the ritual of the daily hour.
The timeline has moved. Cognito’s earlier guidance was a topline readout in “mid-2026.” The current language is “before the end of the year.” A slip of a few months is ordinary in trial logistics and says nothing about the result. It does mean that the date to watch is now a December date, not a summer one.
What a readout would mean beyond the clinic
The 40 Hz number has escaped the lab. This week Universal Music and Apple Music launched “Pop Therapy,” 151 chart songs with embedded beats sorted into three bands, including “gamma” for focus. Sleep apps, meditation apps, and sound-bath practitioners now sell “gamma” the way they sold “theta” five years ago.
Keep two things separate. Driving the brain of a person with Alzheimer’s with synchronized light and sound for an hour a day under a trial protocol is one claim. Playing a song with a 40 Hz pulse mixed into it for a healthy adult who wants to concentrate is another. HOPE tests only the first.
A University of Alabama at Birmingham explainer on music and focus quotes researcher Visscher making the general point: any auditory stimulation can change neural oscillations. That is true, and it is also the problem. Changing a rhythm on an EEG is easy. Showing that the change does anything for a person is the whole of the work, and it is the part the wellness market skips.
If HOPE is positive, the device will likely reach the market, and 40 Hz will become the first brain-rhythm therapy with pivotal-trial evidence behind it. Expect every “gamma” product to cite it. Read the fine print: the result will apply to a sham-controlled protocol in diagnosed Alzheimer’s patients, at a dose of about an hour a day, over a year. It will say nothing about focus beats in a pop song.
If HOPE is negative, the honest conclusion is that a decade of mouse data and a 76-person feasibility study did not translate, which is the most common fate of Alzheimer’s interventions. The “gamma” products will not disappear; their marketing never depended on the trial. But the one piece of evidence they could have pointed to will be gone.
If the result is mixed, with, say, an EEG effect and a brain-volume effect but no clear clinical benefit, the argument will move to whether biomarkers count. For a disease with few options, that argument will be loud, and the right question to keep asking is whether patients and their families can tell the difference.
The honest read
Nothing about the 40 Hz story is proven, and nothing about it is silly. The mouse work is real science from a serious lab. The feasibility data are encouraging in the way feasibility data usually are. The money, $105 million in a Series C led by Morningside in March, is a bet by investors who have seen the unpublished details, which is informative and not decisive.
What we have is a well-designed trial of a plausible idea, with a date attached. That is rarer in this field than it should be.
What to watch
Cognito’s topline HOPE announcement, due before 2026 ends. Three things to check in it: whether the primary clinical endpoint, not just EEG or MRI, separated from sham; the absolute point difference on the scales, not the relative percentage; and how many patients completed the full protocol. If the release leads with a percentage and no absolute number, wait for the paper.
